关注
Jens Hoffmann
Jens Hoffmann
Experimental Pharmacology & Oncology Berlin-Buch
在 epo-berlin.com 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Z Culig, J Hoffmann, M Erdel, IE Eder, A Hobisch, A Hittmair, G Bartsch, ...
British journal of cancer 81 (2), 242-251, 1999
4911999
Establishment of patient-derived non–small cell lung cancer xenografts as models for the identification of predictive biomarkers
I Fichtner, J Rolff, R Soong, J Hoffmann, S Hammer, A Sommer, M Becker, ...
Clinical cancer research 14 (20), 6456-6468, 2008
3552008
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
M Schütte, T Risch, N Abdavi-Azar, K Boehnke, D Schumacher, M Keil, ...
Nature communications 8 (1), 14262, 2017
3082017
Total synthesis and antitumor activity of ZK‐EPO: the first fully synthetic epothilone in clinical development
U Klar, B Buchmann, W Schwede, W Skuballa, J Hoffmann, RB Lichtner
Angewandte Chemie 118 (47), 8110-8116, 2006
1662006
Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor
IE Eder, J Hoffmann, H Rogatsch, G Schäfer, D Zopf, G Bartsch, H Klocker
Cancer gene therapy 9 (2), 117-125, 2002
1372002
Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist
U Fuhrmann, H Hess-Stumpp, A Cleve, G Neef, W Schwede, J Hoffmann, ...
Journal of medicinal chemistry 43 (26), 5010-5016, 2000
1362000
Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
R Schmieder, J Hoffmann, M Becker, A Bhargava, T Müller, N Kahmann, ...
International journal of cancer 135 (6), 1487-1496, 2014
1322014
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone
J Hoffmann, I Vitale, B Buchmann, L Galluzzi, W Schwede, L Senovilla, ...
Cancer research 68 (13), 5301-5308, 2008
1242008
Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models.
M Schirner, J Hoffmann, A Menrad, MR Schneider
Clinical cancer research: an official journal of the American Association …, 1998
1201998
Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer
J Hoffmann, R Bohlmann, N Heinrich, H Hofmeister, J Kroll, H Künzer, ...
Journal of the National Cancer Institute 96 (3), 210-218, 2004
1122004
A Highly Sensitive Model for Quantification of in Vivo Tumor Angiogenesis Induced by Alginate-encapsulated Tumor Cells
J Hoffmann, M Schirner, A Menrad, MR Schneider
Cancer research 57 (17), 3847-3851, 1997
941997
Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases
J Hoffmann, I Fichtner, M Lemm, P Lienau, H Hess-Stumpp, A Rotgeri, ...
Neuro-oncology 11 (2), 158-166, 2009
922009
Cloning and heterologous expression of the aranciamycin biosynthetic gene cluster revealed a new flexible glycosyltransferase
A Luzhetskyy, A Mayer, J Hoffmann, S Pelzer, M Holzenkämper, B Schmitt, ...
ChemBioChem 8 (6), 599-602, 2007
742007
Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures
D Schumacher, G Andrieux, K Boehnke, M Keil, A Silvestri, M Silvestrov, ...
PLoS Genetics 15 (3), e1008076, 2019
732019
A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the m TOR inhibitor everolimus as potential new treatment option
K Klinghammer, JD Raguse, T Plath, AE Albers, K Joehrens, A Zakarneh, ...
International journal of cancer 136 (12), 2940-2948, 2015
642015
Studies on the development of resistance to the pure antiestrogen Faslodex™ in three human breast cancer cell lines
A Sommer, J Hoffmann, RB Lichtner, MR Schneider, K Parczyk
The Journal of steroid biochemistry and molecular biology 85 (1), 33-47, 2003
592003
Choosing wisely–Preclinical test models in the era of precision medicine
K Klinghammer, W Walther, J Hoffmann
Cancer treatment reviews 55, 36-45, 2017
542017
Steroidhormone receptors as targets for the therapy of breast and prostate cancer—recent advances, mechanisms of resistance, and new approaches
J Hoffmann, A Sommer
The Journal of steroid biochemistry and molecular biology 93 (2-5), 191-200, 2005
532005
Subcellular distribution of epothilones in human tumor cells
RB Lichtner, A Rotgeri, T Bunte, B Buchmann, J Hoffmann, W Schwede, ...
Proceedings of the National Academy of Sciences 98 (20), 11743-11748, 2001
522001
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
C Swanton, JM Larkin, M Gerlinger, AC Eklund, M Howell, G Stamp, ...
Genome medicine 2, 1-10, 2010
482010
系统目前无法执行此操作,请稍后再试。
文章 1–20